Innoviva reported a 44% year-over-year growth in royalty revenues, driven by the strength and resilience of its respiratory assets partnered with Glaxo Group Limited (GSK). The company deployed over $400 million in strategic investments and executed on its strategy of creating shareholder value through operational excellence.
Royalty revenues increased by 44% year-over-year.
RELVAR®/BREO® ELLIPTA® global net sales increased significantly, with U.S. net sales driven by a favorable adjustment and non-U.S. sales increasing by 13%.
ANORO® ELLIPTA® global net sales increased by 7%, with non-U.S. sales increasing by 25%.
TRELEGY® ELLIPTA® global net sales increased by 69%, driven by strong volume growth and a favorable adjustment in the U.S. as well as strong launches in non-U.S. markets.
This press release contains forward-looking statements regarding goals, plans, objectives, and future events, which are subject to risks, uncertainties, and assumptions that may cause actual results to differ materially.
Analyze how earnings announcements historically affect stock price performance